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Activating mutations in BRAF kinase are common in melanomas. Clinical trials with PLX4032, the mutant-BRAF inhi-
bitor, show promising preliminary results in patients selected for the presence of V600E mutation. However, activat-
ing V600K mutation is the other most common mutation, yet patients with this variant are currently excluded from
the PLX4032 trials. Here we present evidence that a patient bearing the BRAF V600K mutation responded remark-
ably to PLX4032, suggesting that clinical trials should include all patients with activating BRAF V600E/K mutations.
Commentary
BRAF is a serine/threonine protein kinase, encoded on
chromosome 7q34, that activates the MAP kinase/ERK-
signaling pathway (see KEGG Pathways Database).
Approximately 42% of melanomas harbor activating
BRAF mutations (see COSMIC Database, Wellcome
Sanger Trust). Most commonly, the valine at amino acid
600 is replaced by glutamate (V600E) through mutation
of a single nucleotide (GTG to GAG). Another known
mutation at this site involves two nucleotides (GTG to
AAG), substituting lysine for valine (V600K) (see Table
1 for statistics on the frequency of these mutations
reported in melanoma). The specific BRAF inhibitor
PLX4032 (Plexxikon Inc., Berkeley, CA) suppresses the
activated oncogenic pathway by inhibiting the ERK
kinase cascade. High objective response rates were
observed in the phase I clinical trial of PLX4032 in the
cohort of melanoma patients selected for tumors with
the V600E mutation, and ongoing phase II and phase III
clinical trials are limited to those patients with BRAF
V600E mutations [1].
The incidence of V600K mutations in melanoma may
be greater than previously assumed. In our series of 138
melanomas isolated from patients with disease of vary-
ing stage, 42 harbored BRAF mutations (determined by
Sanger dideoxy sequencing). Of these, 69% carried the
V600E mutation (15 homozygous), while the remaining
28.6% carried the V600K variant (8 homozygous), and
one carried the V600R (AGG/AGG) mutation. Of note,
none of the samples are V600E/V600K heterozygotes,
meaning that the V600K mutation did not arise from a
second alteration at the site of an existing V600E. Alto-
gether, the combined studies show that BRAF V600K
mutations are present in 6-30% of melanoma tumors
(Table 1). This broad range cannot be explained by var-
iation in the ratio of primary versus metastatic melano-
mas or by the different methods used for sequencing
(Table 1). Although different methods to detect the
mutation were used, most of the studies validated the
observations by Sanger dideoxy sequencing. Curiously,
the BRAF mutations present in about 84% of nevi are
reported to be of the V600E type [2,3]. Likewise, in our
cohort of 14 congenital nevi, we also detected four with
BRAF mutations, all heterozygous V600E. Therefore, it
is possible that the V600E and V600K mutant melano-
mas arise from precursor lesions.
PLX4032 is a small molecule inhibitor targeting the
activated form of BRAF [4]. In our recent studies on the
effects of PLX4032, we demonstrated that the high
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mutants in melanoma cells is suppressed by treatment
with PLX4032 [5]. PLX4032 is also known for its para-
doxical effect on cells with wild-type BRAF, in which
RAF1 is activated (reviewed in [6]). We showed that in
BRAF wild-type melanoma cells, PLX4032 stimulated the
downstream intracellular signaling pathway, causing cell
detachment and motility in metastatic melanoma cells
and enhancing cell proliferation in primary melanomas
carrying NRAS Q61L mutations. These paradoxical
effects highlight the importance of tailoring treatment to
the specific genetic composition of the tumor [5].
One of our patients with locally advanced unresectable
melanoma involving the skin of the left chest wall, pro-
gressing after treatment with topical imiquimod and sys-
temic temozolomide, was referred to another institution
for a phase II clinical trial of PLX4032. As part of the
eligibility requirements of the trial, paraffin-embedded
t i s s u ef r o mab i o p s yo fac u t a n e o u sl e s i o nw a st e s t e d
and shown to be positive for the BRAF V600E mutation.
The patient was treated and achieved an excellent clini-
cal response to PLX4032, associated with substantial
r e d u c t i o ni nt h et u m o rb u r d e na n dp a i nf r o mt h e
lesions. Figure 1 shows the cutaneous lesions before and
after treatment with PLX4032. A portion of the tumor
was also collected for laboratory research studies
according to a protocol approved by Yale University
Human Investigations Committee. Written informed
consent was obtained from the patient for publication of
this case report and accompanying images. A copy of
the written consent is available for review by the Editor-
in-Chief of this journal. Upon retesting for BRAF










34 25 (73.5) 4 (11.8) 5 (14.7) Spittle et al. [7] Pyrosequencing,
validated by Sanger dideoxy sequencing
10 9 (90.0) 1 (10.0) 0 (0.0) Hay et al. [8] Melting point analysis, validated by Sanger dideoxy
sequencing
44 34 (77.3) 9 (20.5) 1 (2.3) Willmore-Payne et al. [9] Amplicon melting analysis, validated by Sanger
dideoxy sequencing
42 29 (69) 12 (28.6) 1 (2.3) Halaban et al. [5] and Halaban,
unpublished
Sanger dideoxy sequencing
50 47 (94.0) 3 (6.0) 0 (0.0) Ugurel et al. [10] Fluorescent capillary SSCP technique
178 143
(80.3)
29 (16.3) 6 (3.4) Total Mutations
Figure 1 Chest wall lesions before treatment with PLX4032 (A) and on the first day of the fifth treatment cycle (B).
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that in fact he carried the V600K allele (Figure 2, assay
repeated for validation).
Conclusions
Our data, and those of others reported in the literature,
indicate that the incidence of BRAF V600K mutations in
melanoma patients appears to be higher than is com-
monly assumed. It can be present in up to 30% of
patients bearing BRAF V600 mutations, potentially
representing up to 10% of all melanoma patients.
Patients with BRAF V600K mutations are currently
excluded from clinical trials with PLX4032, although the
assay methodology used for the trial may not discrimi-
nate between the V600E and V600K mutations. Our
preclinical data demonstrating similar kinase activity of
the V600K and V600E mutations, together with clear
evidence of clinical activity of PLX4032 in a patient with
a documented V600K mutation, suggest that melanoma
patients with V600K mutations should be included in
current and future trials of BRAF inhibitors.
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Figure 2 Electropherogram from Sanger dideoxy sequencing showing the patient’s melanoma tumor BRAF codon 600 mutation
(AAG/GTG), encoding V600K/WT protein.
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